Arcturus Therapeutics Announces the Formation of its Vaccine Platform Scientific Advisory Board
Renowned experts in virology, infectious disease, vaccine development and public health to support Arcturus’ COVID-19 vaccine program, LUNAR-COV19
Company remains on track to begin clinical trial for COVID-19 vaccine this summer
“We are proud to have such an accomplished and diverse group of scientific, clinical and public policy experts joining our
“Our differentiated self-replicating mRNA-based approach has the potential to require only a single administration at very low doses to result in potent humoral and cellular immunity. I look forward to working closely with our
Arcturus’ new
Jeff Colyer , M.D., CEO ofVirtus Consultants ; former Governor ofKansas Ooi Eng Eong , Ph.D., BMBS, FRCPath, Professor and Deputy Director of the Emerging Infectious Diseases Programme at theDuke-NUS Medical School Frederick G. Hayden , M.D., FACP, Professor Emeritus of Clinical Virology and Medicine atVirginia University School of Medicine Peter A. Patriarca , M.D., Principal of Immuno-Vax and Senior Affiliate Consultant with theBiologics Consulting Group Robert T. Schooley , M.D., Professor of Medicine and Senior Director of International Initiatives at theUniversity of California San Diego Jonathan Smith , Ph.D., Chief Scientific Officer at VLP Therapeutics
Additional information and biographies are available at https://arcturusrx.com/about-arcturus/advisors/
About Arcturus Therapeutics
Founded in 2013 and based in
Forward Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact included in this press release, including those regarding the Company’s expected performance, the Company’s development of any specific novel mRNA therapeutics, the Company’s efforts to develop a vaccine against COVID-19, and therapeutic potential thereof, based on the Company’s mRNA therapeutics, the forecasted safety, efficacy, characteristics or reliability of a vaccine against COVID-19, were one to be successfully developed based on the Company’s mRNA therapeutics, the timing and availability of a vaccine against COVID-19 were one to be successfully developed based on the Company’s mRNA therapeutics, the potential initiation of human trials of a vaccine against COVID-19 based on the Company’s mRNA therapeutics, the timing of initiation of human trials of a vaccine against COVID-19 based on the Company’s mRNA therapeutics, the potential market impact of a vaccine against COVID-19 based on the Company’s mRNA therapeutics and the impact of general business and economic conditions are forward-looking statements. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements such as the foregoing and you should not place undue reliance on such forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties, including those discussed under the heading "Risk Factors" in Arcturus’ Annual Report on Form 10-K for the fiscal year ended
Contact
(858) 900-2682
IR@ArcturusRx.com
Kendall Investor Relations
(617) 914-0008
ctanzi@kendallir.com
Source: Arcturus Therapeutics Holdings Inc.